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Abstract: Radiation-induced (RI) tissue injuries can be caused by radiation therapy, nuclear accidents or radiological terrorism.
Notwithstanding the complexity of RI pathophysiology, there are some effective approaches to treatment of both acute and
chronic radiation damages. Cytokine therapy is the main strategy capable of preventing or reducing the acute radiation
syndrome (ARS), and hematopoietic growth factors (GF) are particularly effective in mitigating bone marrow (BM) aplasia
and stimulating hematopoietic recovery. However, first, as a consequence of RI stem and progenitor cell death, use of cytokines
should be restricted to a range of intermediate radiation doses (3 to 7 Gy total body irradiation). Second, ARS is a global illness
that requires treatment of damages to other tissues (epithelial, endothelial, glial, etc.), which could be achieved using pleiotropic
or tissue-specific cytokines. Stem cell therapy (SCT) is a promising approach developed in the laboratory that could expand
the ability to treat severe radiation injuries. Allogeneic hematopoietic stem cell transplantation (BM, mobilized peripheral
blood and cord blood) transplantation has been used in radiation casualties with variable success due to limiting toxicity related
to the degree of graft histocompatibility and combined injuries. Ex vivo expansion should be used to augment cord blood graft
size and/or promote very immature stem cells. Autologous SCT might also be applied to radiation casualties from residual
hematopoietic stem and progenitor cells (HSPC). Stem cell plasticity of different tissues such as liver or skeletal muscle, may
also be used as a source of hematopoietic stem cells. Finally, other types of stem cells such as mesenchymal, endothelial stem
cells or other tissue committed stem cells (TCSC), could be used for treating damages to nonhematopoietic organs.
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Introduction 
Acute exposure to high dose of ionizing radiation (IR)
leads to acute radiation syndrome (ARS) which is known
as a triple neurovascular, hematologic and gastro-intes-
tinal (GI) syndrome. ARS should be considered to be a
global illness involving multiple cell communication
networks. Indeed, in addition to inducing an early,
strong, inflammatory process, high doses of IR induce
sequential, deleterious effects responsible for a delayed
multiple organ dysfunction syndrome (MODS). There-
fore, the medical management of radiation casualties is
difficult due to the complexity of RI pathophysiology
[10, 21, 35, 42]. Until now, only hematopoietic syn-
drome can be counteracted by available symptomatic
and/or etiologic therapies [32]. The initiation of treat-
ment after radiation exposure is based on presenting
clinical signs and symptoms, and rate of decline in
absolute lymphocyte count. Within a few days after
damage, specific treatment including cytokine therapy
is recommended for moderate to severe myelosuppress-
ion [16, 42]. However, the higher the radiation dose, the
weaker the efficacy of pure hematopoietic GFs, because
there are too few residual HSPCs left to respond to
cytokine administration. Thus, severe cases of
myeloablation require stem cell therapy (SCT). 
This rationale can be extended to radiation dam-
ages to nonhematopoietic tissues. Injuries caused by
intermediate doses of radiation could be cured by
means of tissue-specific cytokines, whereas severe
damages due to high doses of radiation would require
SCT. For example, serious radiological burns have to
be treated specifically using skin graft. Endothelial
progenitor cell mobilization or transplantation may be
another way to promote vascular regeneration [19]. In
fact, any therapeutic approach should take into account
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the integrated response to radiation by the organism, invol-
ving multiple networks of cooperation and regulation.
Current status of therapies for ARS
Supportive care, including blood transfusion, fluids and
electrolytes administration, antibiotic and antiviral ther-
apy, remains the basis of medical management [10, 21,
35, 42], in particular in the case of combined injuries
(i.e., radiation injury with significant mechanical trauma
and/or burns).
The rationale for cytokine therapy is the presence of
residual HSPCs in BM areas even after total body irradi-
ation (TBI), due to the constitutive heterogeneity of dose
distribution, notably accounted for by the attenuation
related to the body’s thickness. Hematopoietic GFs have
been given to three dozen accidentally irradiated casual-
ties so far [21], but the clinical experience mainly con-
cerns GM-CSF and G-CSF. Consensus treatment
guidelines have been lately established in Europe and
the USA [10, 16, 21, 32, 42] which recommend that
G-CSF be administered soon after exposure until granu-
locyte and/or platelet (PLT) recovery. Treatment recom-
mendations are summarized in Table 1. 
Allogeneic hematopoietic stem cell transplantation
using BM, mobilized peripheral blood (PB) and cord
blood (CB) cells, has been performed in radiation ca-
sualties exhibiting no signs of hematopoietic recovery
[11, 33]. However, immune conflicts associated with T
cell alloreactivity account for the toxicity of such ther-
apy. Moreover, allogeneic stem cell transplantation is
contra-indicated in the case of heavy signs of combined
toxicity (burns, GI failure) that lead to poor outcomes
[42].
Which place for SCT in the treatment of ARS?
SCT is a large therapeutic strategy [40] including non-
manipulated stem cell transplantation (without or with a
preliminary step of selection) and ex vivo expanded stem
and progenitor cell transplantation, the latter being an-
other way of using cytokines. Transient or permanent
cell replacement can be sought in accidentally irradiated
victims for whom the same challenges have to be taken
up as those reported years ago [17].
Treatment of myelosuppression: from
stimulation of residual HSPC to hematopoietic
tissue replacement
G-CSF and its pegylated form, Peg-filgrastim (designed
to exert a prolonged pharmacologic activity [24]) are
recommended by the consensus treatment guidelines to
stimulate residual hematopoiesis. New approaches to
cytokine-based treatment of accidentally irradiated vic-
tims have been proposed, particularly to prevent HSPC
from apoptosis that has been shown to play a major role
in cell death soon after irradiation [5, 13, 20, 26, 36].
Thus, we have developed the concept of "emergency
antiapoptotic cytokine therapy" (EACK), based on in
vitro studies showing the great ability of 4 cytokines in
combination (4F), stem cell factor (SCF), FLT3-ligand
(FL), thrombopoietin (Tpo) and interleukin-3 (IL-3), to
mitigate RI apoptosis at HSPC level and further promote
balanced differentiation [13]. We have lately reported
the ability of early 4F injection (2 hours + 24 hours after
TBI) to rescue mice irradiated at lethal dose 90% from
hematopoietic death with persistent benefit regarding
long-term survival [20]. In 5 Gy gamma irradiated ma-
caques [15], 4F, given as an early (2 hours) single
administration, was shown to counteract HSPC cell
death in vivo, abrogate the 3 week period of aplasia
experienced by untreated controls, and stimulate re-
covery of all hematopoietic lineages. No apparent im-
pairment of the long-term hematopoietic status and stem
cell pool was observed in treated monkeys. Moreover,
4F is still efficient when its single administration is
delayed until 48 h after TBI, and partial preservation is
observed in 7 Gy irradiated monkeys treated at 2 hours
[22]. EACK should be optimized to ensure the survival
of individuals exposed to lethal radiation doses, by ad-
dition or substitution of different cytokines.
The extent of BM damage is the limiting factor for
hematopoietic GF efficacy. Allogeneic stem cell trans-
plantation is made necessary when residual hemato-
poiesis is too low to provide any sign of hematopoietic
recovery in response to cytokine administration [10, 35,
42]. However, whether SCT should aim at providing
permanent hematopoietic tissue replacement is very dif-
ficult to address at the time of transplantation. Indeed,
most of transplanted victims showed transient evidence
of donor cell engraftment, followed by autologous he-
matopoietic recovery [33, 42].
What kind of stem cells can be used for hemato-
poietic recovery? According to hematologists, BM, PB
and CB HSPCs can be used. There have been too few
cases of transplantation of PB and CB cells in radiation
casualties so far to specify the best source of stem cells,
if any, in terms of homing and repopulation potential
[17, 29]. More critical is the degree of HLA matching.
Syngeneic and geno-identical related donors are
preferred. In absence of the former, matched unrelated
donors shall be used. The CD34+ cell threshold to be
grafted is 2×106/kg cells. It is compulsory to avoid the
development of graft versus host disease (GVHD).
Therefore, in the case of mobilized PB, HSPCs should
be depleted of T-cells using CD34+ cell selection. Infu-
sion of allogeneic MSCs may reduce the risk of GVHD
[30].
The role of ex vivo expansion in this context remains
to be determined with respect to stem cell expansion,
stem cell phenotype manipulation (e.g. upregulation of
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cell adhesion molecules or chemokine receptors) or
progenitor cell proliferation. As for CB, ex vivo manipu-
lation is a prerequisite for transplantation in adults.
Based on clinical trials in cancer patients receiving an
autologous graft [38], co-transplantation of both non
manipulated and ex vivo expanded HSPCs from the
same allogeneic donor, may be beneficial to prevent the
period of pancytopenia while ensuring long-term re-
covery. 
Autologous SCT might also be applied to radiation
casualties provided a sufficient amount of residual
HSPCs is collected after irradiation and these cells are
then efficiently expanded ex vivo. Different laboratories
have performed feasibility studies in animal models [3,
4]. In this context, co-cultures on stromal or endothelial
cell layers have been shown to provide a definitive
advantage to the graft [6, 8]. We have also shown that
co-culture of irradiated baboon CD34+ cells on MSCs
and co-transplantation to lethally irradiated recipients
led to increased PLT recovery [14]. Nevertheless, this
strategy remains questionable due the small size of
produced grafts.
TCSC [28] or totipotent stem cells have been de-
scribed as new sources of stem cells [31]. In particular,
hematopoietic potential of the liver and the skeletal
muscle has been evaluated, mainly to a purpose of
autologous transplantation in oncological settings [9,
25]. Different methodologies have been pursued invol-
ving unselected mononuclear cells (MNC), CD34+ cells
or "side population" (SP) cells. In fact, hematopoietic
capacity of adult human skeletal muscle appears to be
negligible [1, 18]. On the contrary, transplantable hema-
topoietic stem cells would reside in human fetal and
adult liver [27, 41]. Our team has lately shown that
transplantation of autologous hepatic MNCs could con-
tribute to granulopoietic reconstitution in a nonhuman
primate model of myelosuppression [23]. Ongoing
studies will address the relevance and effectiveness of
such stem cell sources for treatment of ARS. 
Treatment of nonhematopoietic damages
IR induce damage to nonhematopoietic tissues (epithe-
lial, endothelial, glial, etc.), which strongly suggests that
therapeutics could include tissue-specific and pleio-
tropic cytokines such as erythropoietin (Epo) and kerati-
nocyte growth factor (KGF) in addition to already cited
hematopoietic GFs, to ensure tissue damage repair and
mitigate the inflammatory processes. These cytokines
should be administered soon after damage in an attempt
to reduce stem and progenitor cell death. Indeed, not
only hematopoietic cells but also cells from non-hema-
topoietic tissues such as BM stromal cell precursors
[34], cryptic epithelial stem cells of the intestinal villi
Table 1. Recommended doses of cytokines for accidentally irradiated casualties
Adults Setting and range of exposure Precautions of use
Filgrastim or G-CSF 5 µg/kg/d 3 to10 Gy (N <100 casualties; 
absence of combined injury) Pregnancy,  prothrombotic 
disorders, significant coronary 
artery disease, ARDS, acute cerebral
ischemia, myeloproliferative and
myelodysplastic syndromes
Pegylated-filgrastim or Peg-G-CSF 6 mg per week 
Sargramostim or GM-CSF 250 µg/m2/d 3 to 7 Gy  (mass casualty 
scenario N>100)
G-CSF + EPO* 40 000UI/week* 2 to 6 Gy in case of combinedlesions (whatever the scenario)
The different cytokine treatments proposed could be used in the range of 2 and 7 Gy TBI. ARDS: acute respiratory distress syndrome (ARDS).
Table 2. Validated and putative sources of stem cells for the treatment of ARS
Stem cell sources Hematopoietic recovery Non hematopoietic recovery(prevention of MODS)
HSPC
Allogeneic BM, T-cell depleted PB, CB (±eX),
SC + ± (TCSC contamination)
eX Autologous BM, PB, SC ±
Autologous SC from non hematopoietic tissues
(liver, muscle...) ± eX ±
Specialized
and 
multipotent SC
MSC
+
(support in co- transplantation
with auto/allo HSPC)
±
Endothelial progenitor cells ±
TCSC ±
HSPC: hematopoietic stem and progenitor cell; MODS: multi-organ dysfunction syndrome; SC : stem cells ; MSC: mesenchymal stem cell;
TCSC : tissue-committed stem cells, eX: ex vivo expansion.
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and endothelial cells of the vasculature [37], undergo
apoptosis following irradiation, which confirms the re-
levance of EACK. Based on high protection observed in
lethally irradiated mice, early and short-term adminis-
tration of Epo and/or KGF combined to antiapoptotic
cytokines may result in durable protection of various
tissues [FH, MD, unpublished results].
However, the prevention of MODS may require lo-
calized or ubiquitous stem and progenitor cells supply.
MSCs have been shown to display a certain level of
plasticity within the mesoderm and beyond. Teams in-
volved in nonhuman primate research have reported
wide but modest biodistribution of MSCs after trans-
plantation in normal and myelosuppressed macaques
and baboons [7, 12].
Finally, we assessed the PB CD34+ cell levels after
EACK therapy and showed significantly higher and
earlier CD34+ cell peak values in treated macaques, sign
of greater recovery level, compared to control irradiated
animals [15]. One should look for early and delayed
endothelial progenitor cell mobilization (CD34+ KDR+)
that might participate in vascular recovery.
Conclusions and perspectives
SCT should be considered in patients severely affected
with ARS (i.e. exposed to 7 to 10 Gy) who do not show
evidence of hematopoietic recovery, are not affected by
severe trauma, burns and GI syndrome, and who have
an appropriate donor. Improvement of cytokine therapy
by using pleiotropic or tissue-specific cytokines capable
of mitigating damages to non hematopoietic organs
might broaden the criteria for the selection of radiation
casualties for SCT. Use of multipotent or tissue-specific
stem cells may be another approach to prevent MODS.
In any case, allogeneic grafts highly enriched in stem
cells would reduce the risk of immune conflicts. 
Gene therapy is another experimental approach. Its
goal is to stimulate hematopoiesis through transient or
durable overexpression of genes encoding cytokines.
This can be achieved by manipulating BM stromal cells
using retroviral or adenoviral vector [2, 39]. The safety
and efficacy of such an approach have to be validated
before going to the clinic.
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